MUC1 is a tumor antigen, overexpressed in approximately 90% of human breast cancers. In normal glandular epithelia, MUC1 is expressed at the apical surface; however, in carcinomas an aberrantly glycosylated form of MUC1 is upregulated and expressed around the entire surface of the cell. Previously, we have shown that a lack of Muc1 significantly delays tumor progression and/or onset in MMTV-PyV-mT and MMTV-Wnt-1 transgenic mice. Here we show that, unlike the models mentioned above, a loss of Muc1 in MMTV-c-Neu mice (MMTV-cNeu/Muc1 
Introduction
During the progression to carcinoma, a change in the cellular profile of gene expression occurs. One gene highly induced during the progression to carcinoma is MUC1. MUC1 is a transmembrane mucin with a heterodimeric structure consisting of a large negatively charged extracellular domain and a smaller subunit consisting of transmembrane and cytoplasmic domains.
MUC1 is found to be overexpressed in approximately 90% of human breast cancers, with a clinical significance of poor patient prognosis (Zotter et al., 1988; McGuckin et al., 1995; Croce et al., 2003) . Further, increases in MUC1 expression at least as high as ten fold have been detected (Hilkens et al., 1984) ; however, the processes responsible for the stimulation of MUC1 expression during cancer are currently unclear. The complexity of MUC1 expression is suggested by the fact that hormones, cytokines, and gene modifications are implicated in its regulation.
A role for MUC1 during tumor progression has been demonstrated in studies utilizing transgenic models of breast cancer. MUC1 is the human designation and Muc1 is the mouse designation. Crossing the MMTVPyV-mT (MTag) and MMTV-Wnt-1 models onto a Muc1 null background affects tumor formation. In the MMTV-PyV-mT model, MMTV-PyV-mT/Muc1 À/À mice display a significantly slower tumor progression and a trend toward decreased metastasis (Spicer et al., 1995) . Moreover, MMTV-Wnt-1 mice on a Muc1 null background display a delay in tumor onset (almost double the time to tumor onset in MMTV-Wnt-1/ Muc1 þ / þ mice) (Schroeder et al., 2003) . Further, in MMTV-Wnt-1 tumors Muc1 associates with b-catenin, suggesting that the cytoplasmic domain of MUC1 may allow MUC1 to facilitate molecular interactions that promote tumorigenesis and metastasis.
Previously, our laboratory demonstrated that MUC1/ ErbB2 complexes are detected in mammary glands from lactating MUC1 transgenic mice. In this experimental model, MUC1 potentiated ErbB signaling, as seen by strong induction of Erk1/2 phosphorylation. ErbB2, as well as MUC1, is overexpressed in human breast cancers, and overexpression is associated with poor prognosis. ErbB2 overexpression occurs in 80% of ductal carcinoma in situ (DCIS) and in 25% of invasive cancers (Slamon et al., 1987; Revillion et al., 1998; Witton et al., 2003) . To examine the functional significance of Muc1 during ErbB2-mediated tumorigenesis, we crossed MMTV-c-Neu mice onto a Muc1-deficient background (MMTV-c-Neu/Muc1 À/À ) or a Muc1 wild-type background (MMTV-c-Neu/Muc1 þ / þ ). We found that the loss of Muc1, unlike previous findings, did not alter tumor progression in the MMTV-c-Neu mice. Surprisingly, MMTV-c-Neu/ Muc1 þ / þ tumors displayed no to very low Muc1 expression, while adjacent normal tissues in the mammary gland expressed expected levels of Muc1, which may explain the lack of an effect of deleting the Muc1 gene on tumor development in this model. The decrease in Muc1 in the MMTV-c-Neu tumors was at the level of mRNA, and it was a tumor-specific event. Siegel et al. previously demonstrated that activating mutations occur with the c-Neu transgene in a tumor-specific manner (Siegel et al., 1994 (Siegel et al., , 1999 Siegel and Muller, 1996) . Thus, we examined if the activation of ErbB2 was responsible for mediating the inhibition of Muc1. We found that transient transfection of human embryonic kidney (HEK) 293/MUC1 cells with activated ErbB2 resulted in repression of MUC1 and that this repression was due to the inhibition of transcriptional activation. These findings suggest that during neoplastic progression, Neu negatively regulates Muc1 expression in the cNeu tumors.
Results
Loss of Muc1 has no effect on tumor onset in MMTV-c-Neu transgenic mice
In order to understand the role of Muc1 in tumor progression and metastasis, we crossed MMTV-c-Neu transgenic mice onto a Muc1 null background. MMTVc-Neu transgenics develop unifocal mammary adenocarcinomas surrounded by a hyperplastic mammary epithelium after a long latency period of approximately 7-12 months (Guy et al., 1992) . The c-Neu transgenic model mimics the human breast cancer situation in that metastases occur in the lung (Guy et al., 1992) . We found that there was no significant difference in the time to tumor onset between MMTV-c-Neu/Muc1 À/À mice and MMTV-c-Neu/ Muc1 þ / þ mice (50% tumor incidence at 39 weeks for MMTV-c-Neu/Muc1 À/À mice and 46 weeks for MMTV-c-Neu/ Muc1 þ / þ mice; P ¼ 0.13 log-rank test) (Figure 1) . Moreover, the rate of metastasis in MMTV-c-Neu mice on Muc1 wild-type or null backgrounds was not significantly different.
Muc1 is not expressed in MMTV-
As loss of Muc1 had no effect on tumor onset or progression in MMTV-c-Neu tumors, we examined the level of expression of Muc1 in MMTV-c-Neu/Muc1
tumors. Mammary carcinomas in the mouse induced by mouse mammary tumor virus show high levels of expression of Muc1 both at the RNA and protein levels (SJ Gendler, unpublished data). Moreover, Spicer et al. showed that MTag mammary carcinomas express high levels of the tumor antigen Muc1 (Spicer et al., 1995) . Unlike the tumor models mentioned before, Muc1 protein was absent (or expressed at very low levels) in the MMTV-c-Neu/Muc1 þ / þ mammary tumors ( Figure 2a) ; however, normal appearing mammary tissue adjacent to the c-Neu tumors displayed strong apical expression of Muc1 (Figure 2b ). We stained a total of 33 MMTV-c-Neu/Muc1 þ / þ mammary tumors and found that two tumors were positive for Muc1 expression, 21 tumors had very low Muc1 expression (Figure 2c ), and 10 tumors were completely negative for Muc1 (Figure 2e ). However, the tumors had strong expression of the Neu transgene by immunostaining (Figure 2d and f) . To quantitate the level of Muc1 protein expressed, immunoblot analysis was performed and it was demonstrated that Muc1 was present at low levels, but high levels of c-Neu were easily detected (Figure 3a) . This result contrasted with the results in the nontransgenic lactating mammary gland and MTag mammary tumor, in which strong Muc1 expression was observed, but low levels of c-Neu were observed (Figure 3a) .
Muc1 mRNA was reduced in MMTV-c-Neu tumors
To examine the mechanism by which Muc1 is downmodulated in the c-Neu-induced tumors, Northern blot analysis of total cellular RNA was performed and showed low levels of Muc1 mRNA expression (Figure 3b ). The expected level of Muc1 expression would be that seen in the positive controls (a mammary gland of a lactating mouse and ET mouse pancreas carcinoma); the observed expression was much lower than expected, suggesting that Muc1 is downregulated at the level of transcription. This was compared with the high levels of keratin 18 and Neu mRNA detected (Figure 3b ). The c-Neu tumors were highly epithelial as shown by their strong expression of keratin 18 mRNA. The decreased Muc1 mRNA paralleled the reduction of Muc1 protein detected in these c-Neu tumors, suggesting that the reductions in steady-state levels of Muc1 RNA lead to decreases in Muc1 protein.
Muc1 expression increased in c-Neu transgenic mice during pregnancy
To determine if overexpression of c-Neu is sufficient to induce the downregulation of Muc1 expression, mammary glands from pregnant MMTV-c-Neu/Muc1 þ / þ Tg mice were analysed. There is an increase in Muc1 expression at day 10 of pregnancy and maximal levels are reached by day 14 of pregnancy. The c-Neu transgene is under the control of the MMTV promoter, suggesting that there should be an increase in the expression of the transgene during pregnancy and lactation, which was what we saw ( Figure 4d) .
Transgenic MMTV-c-NeuMuc1 þ / þ mammary glands taken at day 15 of pregnancy showed the expected high level of Muc1 expression (Figure 4a and c). The amount of Muc1 expressed at day 15 of pregnancy was equivalent to the amount of expression in the MTag tumor ( Figure 4c ). The Muc1 staining pattern of the transgenic pregnant mammary gland paralleled the pattern found in the nontransgenic pregnant mammary gland, where Muc1 stained predominantly on the apical side of the lumenal cells (Figure 4a and b). These data suggested that overexpression of Neu was not sufficient to downregulate Muc1 and that a tumor-specific event was responsible for the decreased Muc1 expression. This is supported by the fact that it has been previously shown that the c-Neu tumors contain extracellular deletions in the juxtamembrane domain that oncogenically activate the c-Neu transgene (Siegel et al., 1994 (Siegel et al., , 1999 Siegel and Muller, 1996) .
Activated ErbB2 induces downregulation of MUC1 expression
To determine whether overexpression or activation of ErbB2 was necessary for ErbB2-mediated inhibition of MUC1, we transiently transfected HEK 293/MUC1 cells with either an empty vector (pcDNA 3.1), wild-type ErbB2 (ErbB2 WT), or activated ErbB2 (ErbB2 VE). The activated ErbB2 contains a point mutation in the transmembrane domain at residue 659 that results in an formaldehyde-agarose gels and transferred onto nylon membranes. The membrane was stained with methylene blue for the 28S ribosomal band for loading control. RNA was hybridized with either a Muc1 probe (pMuc10), ErbB2 probe, or a keratin 18 probe amino acid change from valine to glutamic acid, and results in ligand-independent signaling and increased kinase activity of ErbB2. This mutation is homologous to the point mutation originally identified in the rat oncogene. Transfection with the empty vector or wildtype ErbB2 did not result in the downmodulation of MUC1 expression ( Figure 5a) ; however, we found that transfection with activated ErbB2 resulted in a dramatic decrease in the expression of MUC1 (Figure 5a ).
ErbB2 signaling inhibits Muc1 transcriptional activation
To investigate the effect of ErbB2 signaling on the transcriptional activity of Muc1, we performed reporter assays in HEK 293 cells with mouse Muc1 promoter deletion/reporter constructs. The mouse and human promoters are well conserved within 500 bp of the transcription start site and have 74% identity (Spicer et al., 1991) . We utilized serial deletions of mouse Muc1 promoter constructs (containing various amounts of 5 0 flanking sequence) in the pGL3 basic vector. The fulllength promoter is denoted À1836/ þ 33 and we arbitrarily took this construct to be 100% for our reporter assays in comparison with the various deletion constructs. Promoter analysis demonstrated that all the deletion constructs had basal activity and were able to drive expression of the reporter gene (data not shown). To determine if overexpression or activation of ErbB2 was responsible for the inhibition of Muc1, we performed reporter assays in HEK 293 cells cotransfected with either an empty vector (control), wild-type ErbB2, or activated ErbB2 (ErbB2 VE). Reporter assays demonstrated that ErbB2 signaling inhibited Muc1 transcriptional activation in a dose-dependent manner. We found that mutationally activated ErbB2 had the greatest inhibition (Figure 5b ). Transient transfection of 0.5 mg of activated ErbB2 resulted in 80% repression, while transfection of 0.5 mg of the wild-type gene resulted in a 40% repression. Addition of more ErbB2 (2.0 mg) was able to induce an 80% repression. These findings are consistent with an earlier report, which showed that transient transfection of ErbB2 could inhibit Muc1 transcriptional activation. Moreover, these data suggest that decreases detected in Muc1 mRNA in MMTV-c-Neu tumors were due to decreases in Muc1 transcription.
Location of the Muc1 promoter region responsible for ErbB2 repression of Muc1
To identify the region necessary for the activated ErbB2-mediated inhibition, we performed reporter assays with Muc1 promoter deletion constructs (Figure 6a ). These assays suggested that the location of the region necessary for ErbB2-mediated inhibition is located between À247 and À108 (Figure 6b ). This region contains a previously identified DNAse I hypersensitive site that was found to correlate with Muc1 expression. Additionally, within this region is an AP-2 site conserved in both the mouse and human genes. Thus these data suggest that an element within the À247/ À108 region is necessary for activated ErbB2-mediated inhibition of Muc1.
ErbB2 and MUC1 expression in human breast tumors
To examine the effect that overexpression of ErbB2 has on MUC1 expression in human breast cancer, we compared the staining pattern of MUC1 and ErbB2 on adjacent sections in five ErbB2-negative (HER2-0) versus five ErbB2-positive (HER2-3 þ ) human breast tumors. The breast cancer sections were examined by a pathologist at Mayo Clinic Scottsdale and were classified according to modified Bloom-Richardson criteria. All cases classified as ErbB2 negative did not display ErbB2 staining (Figure 7b ), while MUC1 staining was observed throughout the tumor sections with strong staining in both membrane and cytoplasmic areas of the tumor cells (Figure 7a) . Moreover, the invasive areas of the breast tumors highly expressed MUC1. Additionally, MUC1 was highly expressed in human breast tumors that overexpress HER2; however, areas of discordant expression between the two proteins were observed. In some areas of the sections ErbB2 staining was very strong (Figure 7d ), while these same areas in adjacent sections showed low to no positive expression for MUC1 (Figure 7c ). Thus, even though all the sections were MUC1 positive, areas of reciprocal expression between ErbB2 and MUC1 were detected.
Discussion
In the MMTV-c-Neu transgenic mouse model we found that crossing the MMTV-c-Neu model onto a Muc1 null background elicited no effect on either tumor onset or tumor progression. This result differed from our previously published results, where we showed that a lack of Muc1 significantly delayed tumor progression and/or onset in MMTV-PyV-mT and MMTV-Wnt-1 transgenic mice (Spicer et al., 1995; Schroeder et al., 2003) . Further characterization of the MMTV-c-Neu/ Muc1 þ / þ tumors revealed that the expression of Muc1 was dramatically decreased, and that this decrease was at the level of mRNA. Muc1 was expressed in the normal mammary gland and high levels of Muc1 were detected in pregnant mammary glands from MMTV-cNeu transgenic mice, suggesting that the inhibition of Muc1 was a tumor-specific event. To address the consequence of overexpression of MUC1 during ErbB2-mediated tumorigenesis, we are currently crossing MMTV-c-Neu transgenic mice with mice that overexpress full-length human MUC1. The MUC1 transgenic animals express a genomic clone of MUC1 that contains the endogenous promoter and all the regulatory sequences necessary to drive expression (Rowse et al., 1998a) . Interestingly, in one bitransgenic animal we found that MUC1 is highly expressed in the normal mammary gland; however, MUC1 is largely absent in the mammary tumor, with staining present in focal areas.
Activating mutations occur with high frequency in the c-Neu transgene in a tumor-specific manner (Siegel and Muller, 1996; Siegel et al., 1999) . These mutations result in activation of the gene and promote receptor dimerization and increased activity. We tested whether overexpression or activation of ErbB2 led to the inhibition of MUC1 expression. Transient transfection of activated ErbB2 into HEK 293/MUC1 cells resulted in a dramatic decrease in MUC1 expression, while transfection of an empty vector or wild-type ErbB2 had no effect on MUC1 expression. Consistent with our data, Engelman et al. (1998) also found that only activated ErbB2 inhibited caveolin-1 expression in cell culture; moreover, caveolin-1 expression was downregulated in MMTV-c-Neu tumors, presumably due to somatic mutations in the transgene. In contrast, Scibetta et al. (2001) found that exogenous overexpression of wild-type ErbB2 in immortalized mammary epithelial cells was sufficient to repress MUC1 expression. Interestingly, they found that ErbB2-mediated inhibition of MUC1 was less effective in breast cancer cell lines. The HEK 293/MUC1 cells we tested highly expressed MUC1 at levels comparable to the MDA-MB-468 breast cancer cell line. This may explain the discrepancy between our findings in HEK 293/MUC1 cells and their findings in the mammary epithelial cells.
Utilizing Muc1 promoter-luciferase constructs in transient transfection assays, we demonstrated that this inhibition was at the transcriptional level. Moreover, we provided evidence that a region located between À247/ À108 in the Muc1 promoter is required for this ErbB2-mediated transcriptional regulation. This À247/ À108 region contains a previously identified DNase I hypersensitive site that has been shown to correlate with MUC1 expression (Shiraga et al., 2002) . Further, this hypersensitive site was also present in transgenic mice expressing the human gene, suggesting that mice express the trans-acting factors that potentially bind to this site (Shiraga et al., 2002) . In the human gene, this hypersensitive site contains a pyrimidine mirror repeat (PMR) that is associated with the formation of H-DNA (Nelson et al., 1996) . Regions of DNA that contain polypyrimidine or polypurine tracts involving a mirror repeat have the capability of forming a triplex structure known as H-DNA (Mirkin et al., 1987) . The formation of H-DNA within promoter regions is thought to be involved in the regulation of gene expression (Larsen and Weintraub, 1982) . In the mouse gene, the PMR is not conserved within the hypersensitive site; however, immediately 3 0 to this region the human and mouse genes are highly homologous, suggesting that this conservation in sequence may reflect an area important for the regulation of expression (Shiraga et al., 2002) . Also within this region an AP-2 site is conserved in the human and mouse genes. AP-2 has both stimulatory and repressive functions; interestingly, the expression of AP-2 has been shown to correlate with the overexpression of ErbB2 in human breast cancer (Turner et al., 1998) . Thus, our findings demonstrate that mutationally activated ErbB2 can regulate MUC1 expression at the level of transcription.
ErbB2 has been shown to induce the loss of epithelial properties in favor of the acquisition of a more mesenchymal phenotype, thus promoting invasion. In vitro, ErbB2 has been shown to regulate negatively epithelial adhesive proteins such as E-cadherin and a2 integrin at the level of transcription in the process of stimulating a cellular program favoring a more mesenchymal phenotype. During tumor development in MMTV-c-Neu mice, somatic mutations in the Neu transgene resulting in the formation of an activated form of ErbB2 may promote an epithelial to mesenchymal transition (EMT), and thus downregulate Muc1. Interestingly, work in MDCK cells, a polarized epithelial cell line, showed that the expression of activated ErbB2 favored a fibroblastic phenotype, while wild-type ErbB2 had no effect on cell morphology (Khoury et al., 2001) . Moreover, snail, a zinc-finger transcriptional repressor activated during EMT, has been shown to inhibit E-cadherin and MUC1 expression (Guaita et al., 2002) . It is somewhat of a paradox then, that despite the fact that MUC1 is an epithelial antigen, it is highly expressed in invasive breast cancers.
Owing to our findings in the MMTV-c-Neu tumors and HEK 293/MUC1 expressing cells, we were interested in examining the effect that overexpression of ErbB2 had, if any, on MUC1 expression in human breast cancers. Both MUC1 and ErbB2 are overexpressed in human breast cancers with a clinical significance. It is interesting to note that MUC1 is highly expressed in invasive disease, while the overexpression of ErbB2 predominates earlier in tumor development. MUC1 is overexpressed in approximately 90% of human breast cancers, while ErbB2 overexpression occurs in 80% of DCIS and 25% of invasive cancers (Slamon et al., 1987; Zotter et al., 1988; Revillion et al., 1998; Witton et al., 2003) . In human cancers, oncogenic activation of ErbB2 is generally thought to occur mostly due to the overexpression of ErbB2, and not activation. However, an alternative form of ErbB2 with increased oncogenic activity has been detected in human breast cancer cell lines and some human breast tumors (Kwong and Hung, 1998; Siegel et al., 1999) . Interestingly, the deletions found in the human gene overlap the somatic mutations that occur in the c-Neu transgene during tumor development in MMTV-c-Neu mice. To determine if ErbB2-mediated inhibition of MUC1 occurs in human breast cancers, we determined MUC1 expression in tumors that overexpressed HER2/Neu and tumors that were negative for HER2/Neu. Examinations of our sample subset of human breast cancers suggested that overexpression of ErbB2 does not result in a global downregulation of MUC1. However, we did find areas with reciprocal expression of ErbB2 and MUC1. Previously, another group studying breast cancer found that the patterns of ErbB2 and MUC1 expression were overlapping, but discordant (Akewanlop et al., 2001) . Thus, because the expression of MUC1 and ErbB2 is not completely concordant, the targeting of both MUC1 and ErbB2 in therapeutic protocols may result in affecting a wider range of breast tumors.
The disparity between the findings in the mouse and human breast tumors may be due to a lower frequency of ErbB2-activating mutations in human tumors. Additionally, unlike human tumors, c-Neu tumors do not contain a significant stromal component. Thus, the differing environments may result in a different gene expression pattern. In vitro, Scibetta et al. showed that activating ras mutations had a negative effect on MUC1 transcriptional activation; however, it is important to note that in human breast cancer, activating mutations in ras are a rare event (Rochlitz et al., 1989; Scibetta et al., 2001) . We found that in c-Neu transgenics, Muc1 was still expressed at high levels during pregnancy, suggesting that the machinery driving the increase in Muc1 expression during pregnancy over-rides any ErbB2-mediated inhibition. These activating signals may be turned on during progression to carcinoma in the human breast and explain why overexpression of ErbB2 does not result in an inhibition of MUC1 expression.
Experimental procedures
Cell culture and DNA constructs HEK 293 cells (purchased from ATCC) and HEK 293/ MUC1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal calf serum, 1% glutamax, 1% pen/strep, 1 mM sodium pyruvate (Life Technologies), and 1 Â nonessential amino acids (Sigma). The medium for HEK 293/ MUC1 cells and HEK 293/vector control cells was supplemented with zeocin 125 mg/ml (Life Technologies). HEK 293/MUC1 cells were generated by cotransfecting HEK 293 cells with a Sac II 10 kb clone of human MUC1 (containing the endogenous promoter and all the regulatory sequences necessary to drive expression; Peat et al., 1992 and pcDNA3.1zeo vector (Invitrogen, Life Technologies) Tumor generation system FVB mice transgenic for the unactivated rat c-Neu protooncogene under the control of the mouse mammary tumor virus promoter (line #202) (a generous gift from Dr W Muller, McMaster University, London, Ontario, Canada) were utilized to examine Muc1 expression during tumor development. The resulting offspring were screened for the presence of the c-Neu transgene by PCR amplification as previously described (Rowse et al., 1998b) . Muc1 null mice were also screened by PCR as previously described (Spicer et al., 1995) . Positive c-Neu males were bred back onto FVB mice homozygous for either Muc1 null or wild-type alleles. Starting at 12 weeks mice were palpated once a week for the presence of mammary tumors. Palpable tumors were measured by calipers, and tumor weight was calculated according to the formula: grams ¼ [(length) Â (width) 2 ]/ 2, where length and width are measured in centimeters. At the end point of E2 g tumor weight, tumors were dissected and a portion was fixed in methacarn for immunohistochemical analysis. The lungs were dissected, fixed in methacarn, and scored for metastasis using a dissecting microscope.
Northern analysis
Total RNA was isolated from tissues dissected from MMTV-c-Neu tumors, lactating mammary gland, ET pancreas tumor, and homogenized in Trizol (Life Technologies). RNA (20 mg) was fractionated on 1.2% formaldehyde-agarose gel and transferred onto a nylon membrane (Zeta probe, Biorad) in 10 Â SSC. The membrane was baked at 801C for 1 h and was crosslinked by UV irradiation. The membrane was stained with methylene blue solution to detect 18S and 28S ribosomal RNA prior to hybridization. Blots were hybridized overnight with a mouse Muc1 probe, pMuc10, a 3 0 cDNA probe to unique sequence (Spicer et al., 1991) , a Neu cDNA probe (a gift from Dr D Lee, University of North Carolina, Chapel Hill, NC, USA), and a keratin 18 cDNA probe (a gift from Dr R Oshima, Burnham Institute, La Jolla, CA, USA).
Immunoblot analysis
Mammary glands and tumors were homogenized in 20 mM HEPES, pH 8.0, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 2 mM sodium ortho vanadate, 50 mM ammonium molybdate, 10 mM sodium fluoride, and a complete inhibitor cocktail (Sigma Chemical Company). Cellular debris was removed by centrifugation at 15 000 g for 3 min. The protein concentration was determined by BCA assay (Pierce) and samples were frozen at À801C. Immunoblots were performed using 100-200 mg of protein extract per sample, separated by electrophoresis on SDS-PAGE gels. Proteins were transferred onto PVDF membranes (Immobilon). Blots were probed with anti-Neu (Sc-284; Santa Cruz Biotechnology) and an Armenian hamster monoclonal antibody to Muc1 cytoplasmic tail, CT2 (Schroeder et al., 2001) .
Immunohistochemistry
Mouse tissues were fixed in methacarn, paraffin embedded (Mayo Clinic Scottsdale Histology Core), and 5 mM sections were cut. Slides were deparaffinized in xylene, rehydrated, blocked in normal goat serum, and incubated with primary antibodies anti-Muc1 monoclonal CT2 and anti-Neu rabbit polyclonal (Santa Cruz Biotechnology) overnight at 41C. Slides were washed in PBS, incubated with HRP-conjugated secondary antibody, washed in PBS, and developed with 3 0 3 0 -diaminobenzidine (Vector Laboratory) and counterstained with Meyers hematoxylin (Sigma Diagnostics, St Louis, MO, USA).
Formalin-fixed, 5 mm paraffin-embedded human breast cancer sections were stained for MUC1 and ErbB2 as follows. ErbB2 staining was performed with the HerceptTest (DAKO). For MUC1 staining, slides were deparaffinized in xylene, rehydrated, blocked in normal goat serum, and incubated with primary antibody anti-MUC1 BC2, a mouse monoclonal antibody that recognizes the epitope APDTR in the tandem repeat in MUC1; BC2 was a kind gift from Dr M McGuckin (University of Melbourne, Australia). Anti-MUC1 BC2 was diluted 1 : 20 000 in PBS with 1.5% normal goat serum (Xing et al., 1989) . Sections were incubated with anti-MUC1 antibody overnight at 41C, followed by 2 Â 1 min PBS washes, 1 h incubation in HRP-conjugated anti-mouse (Pierce) diluted 1 : 500 in PBS with 1.5% normal goat serum, followed by 2 Â 1 min PBS washes. Slides were developed with 3 0 3 0 -diaminobenzidine (Vector Laboratory, Burlingame, CA, USA) and counterstained with Meyers hematoxylin (Sigma) and followed by 10 min of water washes. Sections were dehydrated and cover slipped in the Mayo Clinic Scottsdale Histology Core Facility. Approval for this study was obtained from the Mayo Institutional Review Board.
Pathological examination
Pathological examination of the breast tumor sections was performed by Dr T Lidner at Mayo Clinic Scottsdale. Sections were graded according to a Modified BloomRichardson criteria (Bloom and Richardson, 1957) .
Analysis of MUC1 expression
HEK 293/MUC1 cells transfected with an empty vector (pcDNA3.1) or wild-type ErbB2 (wild-type), or activated ErbB2 (ErbB2 VE) using lipofectamine (Invitrogen, Life Technologies) were analysed 48 h posttransfection for MUC1 expression. MUC1 levels in transfected cells were determined by immunoprecipitation and immunoblotting as described above with the following exceptions. Immunoprecipitations were performed from 250 mg of protein lysate, using Protein A/G agarose conjugate (Invitrogen, Life Technologies). Immunoprecipitations were performed with anti-MUC1 (CT2), followed by subsequent immunoblot analysis with CT2. Immunoblot analysis for ErbB2 was performed with anti-Neu, Sc-284 (Santa Cruz Biotechnology).
Transient transfections and reporter assays
The effect of ErbB2 signaling on Muc1 transcriptional activity was measured by cotransfection of empty vector (pcDNA3.1), wild-type ErbB2 (ErbB2 WT), or activated ErbB2 (ErbB2 VE) with reporter plasmid containing the Muc1 promoter linked to firefly luciferase (pMuc1-LUC) constructs into HEK 293 cells using lipofectamine according to the manufacturer's instructions (Invitrogen, Life Technologies). Cotransfections included a CMV-b galactosidase plasmid (Clontech, Palo Alto, CA, USA) as a normalization control for transfection efficiency. At 48 h following transfection, firefly luciferase activity was measured using the Luciferase Reporter Assay System according to the manufacturer's instructions (Promega, Madison, WI, USA) on a lumicount microplate luminometer (Parkard, Meridan, CT, USA). b-galactosidase activity was measured with the GalScreen Reporter Gene Assay System according to the manufacturer's instructions (Tropix, Bedford, MA, USA) on a lumicount microplate luminometer (Parkard). The total micromolar amount of DNA transfected per sample was standardized with the addition of an empty vector. The experiments were repeated at least three times.
